Skip to main content

Table 2 The effect of risk factors on development of myocardial dysfunction (SF < 29 %) – Univariate and multiple logistic regression analysis

From: Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy

Risk Factorsa, b Unadjusted OR 95 % CI p-value Adjusted OR 95 % CI p-value
Years post-chemo 0.99 0.96, 1.00 0.87 --- --- ---
Age at Diagnosis 1.04 1.00, 1.08 0.04 1.00 0.96, 1.05 0.99
Gender 1.16 0.74, 1.83 0.51 --- --- ---
Cumulative dose 3.36 2.06, 5.49 <0.001 3.27 1.94, 5.49 <0.001
Radiation to chest 1.82 0.99, 3.33 0.05 1.50 0.76, 2.96 0.24
Vinca Alkaloids 0.80 0.46, 1.37 0.41 --- --- ---
BMT 2.98 1.57, 5.64 0.001 2.57 1.24, 5.30 0.01
Previous heart diseasec 2.09 1.05, 4.15 0.04 1.87 0.85, 4.12 0.12
Cardio-protective drugs 1.86 0.80, 4.32 0.15 --- --- ---
  1. aRisk factors for cardiotoxicity include increased length of post-chemotherapy interval (years), younger age at diagnosis, female gender, total cumulative dose ≥240 mg/m2, radiation therapy to the chest, treatment with vinca alkaloids, bone marrow transplant, previous heart disease, non-use of cardio-protective drugs
  2. bThe 5 significant risk factors upon univariate analysis were selected as covariates for the multiple logistic regression model (younger age at diagnosis, total cumulative dose anthracyclines > 240 mg/m2, radiation to the chest, BMT and previous heart disease)
  3. cPrevious heart disease defined as: presence of congenital heart disease, pericardial effusion/tamponade, SVC syndrome, myocardial dysfunction prior to chemotherapy